Using microRNAs to personalize heart transplant medicines in children
Part of Heart & circulation clinical trials.
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child is 18 or younger when placed on the heart transplant waiting list.
- It has been between 10 and 50 days since the heart transplant.
- You are willing to be followed at the transplant center for at least one year after joining the study.
- You or your caregiver can follow the study schedule and procedures.
- You have not had a transplant of more than one organ, a previous organ transplant, or an active infection requiring hospital or IV treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This trial uses precise, personalized approaches to manage heart transplant recipients. It involves taking a small heart muscle sample (a biopsy) to monitor for rejection or routine checks.
This study tests whether a heart MRI can detect early signs of organ rejection after a heart transplant. If successful, it could reduce the need for frequent biopsies.
This study uses tiny particles called extracellular vesicles (which cells release) to check for signs of organ rejection after a heart transplant, aiming for a safer and less invasive alternative to biopsies.
This study looks at how to better manage anti-rejection medicines (tacrolimus and mycophenolate) in children and teens who have had an organ transplant. It uses text messages to help monitor drug levels, which might make treatment easier and safer.
Hear when a new Cardiac Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.